Cristina SolÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5317479/publications.pdf

Version: 2024-02-01

32 papers	1,684 citations	430442 18 h-index	454577 30 g-index
32 all docs	32 docs citations	32 times ranked	1679 citing authors

#	Article	IF	Citations
1	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
2	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. Journal of Hepatology, 2018, 69, 1250-1259.	1.8	152
3	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
4	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in PatientsÂWith Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1792-1800.e3.	2.4	127
5	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2017, 15, 438-445.e5.	2.4	125
6	Neutrophil Gelatinaseâ€Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70, 319-333.	3.6	114
7	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Scientific Reports, 2016, 6, 32341.	1.6	101
8	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. PLoS ONE, 2015, 10, e0128145.	1.1	97
9	Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology, 2021, 160, 206-218.e13.	0.6	89
10	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International, 2019, 39, 1246-1255.	1.9	64
11	Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. Journal of Hepatology, 2015, 63, 593-600.	1.8	53
12	Management of uninfected and infected ascites in cirrhosis. Liver International, 2016, 36, 109-115.	1.9	43
13	Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. Journal of Hepatology, 2020, 72, 1132-1139.	1.8	43
14	Hepatorenal syndrome in the era of acute kidney injury. Liver International, 2018, 38, 1891-1901.	1.9	42
15	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 914-920.	1.8	35
16	Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. Clinical and Translational Gastroenterology, 2020, 11, e00159.	1.3	32
17	Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. Scientific Reports, 2017, 7, 1829.	1.6	30
18	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. Journal of Hepatology, 2022, 76, 107-114.	1.8	21

#	Article	IF	Citations
19	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. PLoS ONE, 2016, 11, e0157371.	1.1	20
20	Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure. JHEP Reports, 2022, 4, 100482.	2.6	14
21	ActualizaciÃ³n en la insuficiencia hepÃ¡tica aguda sobre crÃ³nica. GastroenterologÃa Y HepatologÃa, 2018, 41, 43-53.	0.2	11
22	Patterns of kidney dysfunction in acuteâ€onâ€chronic liver failure: Relationship with kidney and patientsâ€™ outcome. Hepatology Communications, 2022, 6, 2121-2131.	2.0	8
23	An Unusual Cause of Acute Severe Hepatitis. Gastroenterology, 2019, 156, e3-e4.	0.6	6
24	Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. Liver International, 2021, 41, 2729-2732.	1.9	6
25	Lack of evidence for a continuum between hepatorenal syndromeÂand acute tubular necrosis. Journal of Hepatology, 2020, 72, 581-582.	1.8	5
26	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Digestive and Liver Disease, 2021, 53, 738-745.	0.4	5
27	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4885.	1.0	5
28	New Strategies for the Management of Decompensated Cirrosis: Longâ€Term Albumin Administration for Everyone?. Hepatology, 2019, 69, 2289-2291.	3.6	2
29	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. Clinics in Liver Disease, 2021, 25, 441-460.	1.0	2
30	Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?. Clinical Gastroenterology and Hepatology, 2020, 18, 1040-1042.	2.4	1
31	Reply to: â€œMidodrine and albumin in decompensated cirrhosis: Down but not outâ€¦â€. Journal of Hepatology, 2019, 70, 812.	1.8	0
32	Reply. Gastroenterology, 2021, 160, 2206.	0.6	0